Over-The-Counter Monograph Drug User Fee Program (OMUFA)

Why It Matters

The increased revenue supports FDA oversight of OTC drug manufacturing, while the fee structure clarifies cost responsibilities for both direct manufacturers and CMOs. Understanding exemptions helps affected firms avoid unnecessary charges.

Key Takeaways

• FY 2025 fee totals $36.467 million.
• Facility fee due June 2, 2025.
• CMO facilities pay two‑thirds of standard fee.
• Fees rose 10% due to inflation and statutory increase.
• Hand‑sanitizer‑only plants exempt if deregistered by Dec 31 2024.

Pulse Analysis

The Over‑The‑Counter Monograph Drug User Fee Program (OMUFA) is a statutory mechanism that funds FDA’s post‑market surveillance of OTC drug manufacturing. Under section 744L of the FD&C Act, any domestic or foreign entity that manufactures finished dosage forms of OTC monograph drugs—whether a stand‑alone producer or a contract manufacturing organization (CMO)—is classified as an OTC monograph drug facility and must remit an annual facility fee. The program explicitly excludes facilities that only produced hand‑sanitizer during the COVID‑19 public‑health emergency and have deregistered before the end of 2024, ensuring that temporary pandemic‑driven operations are not penalized.

For fiscal year 2025, FDA set the total target revenue at $36.467 million, a 10 % increase over the prior year. The rise reflects a $3 million statutory uplift and a $1.2 million inflation adjustment, applied after calculating the number of fee‑liable facilities using eDRLS registration data. Standard facilities face the full per‑facility rate, while CMOs are charged two‑thirds of that amount, recognizing their indirect market role. This fee structure spreads the cost of regulatory oversight across the supply chain, but it also adds a measurable expense that manufacturers must incorporate into budgeting and pricing strategies.

Companies should verify their registration status, confirm their FDA Establishment Identifier (FEI), and assess whether any exemptions apply before the June 2, 2025 deadline. Prompt communication with FDA’s collections office can resolve disputes over fee liability. As the FDA continues to adjust fee levels for inflation and statutory mandates, firms that proactively monitor regulatory updates will better manage compliance costs and avoid surprise assessments, positioning themselves competitively in the evolving OTC market.